Tilray Brands Inc banner

Tilray Brands Inc
TSX:TLRY

Watchlist Manager
Tilray Brands Inc Logo
Tilray Brands Inc
TSX:TLRY
Watchlist
Price: 10.82 CAD 14.62% Market Closed
Market Cap: CA$1.3B

EV/OCF

-19.4
Current
22%
Cheaper
vs 3-y average of -24.9

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-19.4
=
Enterprise Value
CA$831.6m
/
Operating Cash Flow
$-44.6m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-19.4
=
Enterprise Value
CA$831.6m
/
Operating Cash Flow
$-44.6m

Valuation Scenarios

Tilray Brands Inc is trading above its industry average

If EV/OCF returns to its Industry Average (14.4), the stock would be worth CA$-8.04 (174% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-186%
Maximum Upside
No Upside Scenarios
Average Downside
180%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple -19.4 CA$10.82
0%
Industry Average 14.4 CA$-8.04
-174%
Country Average 16.7 CA$-9.32
-186%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Tilray Brands Inc
TSX:TLRY
808.8m CAD -19.4 -0.6
US
Eli Lilly and Co
NYSE:LLY
867B USD 53.5 42
US
Johnson & Johnson
NYSE:JNJ
555.4B USD 23.7 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 14.7 19.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 21.8 29.1
CH
Novartis AG
SIX:NOVN
221.8B CHF 15.5 20
US
Merck & Co Inc
NYSE:MRK
283.6B USD 19.2 15.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.9 10.7
US
Pfizer Inc
NYSE:PFE
152.4B USD 17.1 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
118.8B USD 10.7 16.9
P/E Multiple
Earnings Growth PEG
US
Tilray Brands Inc
TSX:TLRY
Average P/E: 22.2
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.1
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 9 518 companies
0th percentile
-27.7
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Tilray Brands Inc
Glance View

Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs. Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.

TLRY Intrinsic Value
14.11 CAD
Undervaluation 23%
Intrinsic Value
Price CA$10.82
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett